Overview

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

Status:
RECRUITING

Trial end date:
2027-03-01

Target enrollment:

Participant gender:

Summary

This is a randomized, parallel-group, double-blind, placebo-controlled, monotherapy study to evaluate the efficacy, safety, and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.

Phase:

PHASE2

Details

Lead Sponsor:

Seaport Therapeutics

Collaborator:

Premier Research Group plc